About Us
Executive Director, Chief Executive Officer: Mr. Eric Tse
-
- Executive Director, Chief Executive Officer: Mr. Eric Tse
- He has served as an Executive Director of Sino Biopharmaceutical Limited since 2019, Chairman of CTTQ Pharma since 2020, and has been the Chief Executive Officer of Sino Biopharmaceutical Limited and Chairman of Beijing Tide Pharmaceutical Co., Ltd. since 2022. He holds a Bachelor's degree in Economics from the Wharton School of the University of Pennsylvania, a Master's degree in Management from Schwarzman College at Tsinghua University, and is a Ph.D. candidate in Social and Administrative Pharmacy at China Pharmaceutical University. He was awarded the "Top 10 Outstanding Chinese American Youth" and "Advanced Individual for Outstanding Contribution to Jiangsu Manufacturing".
Mr. Eric Tse is currently a member of the Beijing Municipal Committee of the CPPCC, a member of the 13th National Committee of the All-China Youth Federation, Vice Chairman of the 12th Committee of the Shaanxi Youth Federation, a member of the 7th Election Committee of the Hong Kong SAR, Vice President of the Hong Kong CPPCC Youth Association, a member of the Digital Economy Committee of the APEC China Business Council, a member of the Presidium of Global Shapers under the World Economic Forum, Vice Chairman of the Science and Technology Innovation Committee of the Belt and Road General Chamber of Commerce, a member of the Y.Elites Association, and Executive Vice President of the Jiangsu Overseas Chinese Entrepreneurs Association.
Since taking over as Chief Executive Officer of Sino Biopharm, Mr. Eric Tse has focused on the four major strategies of "organizational integration, comprehensive innovation, internationalization, and digitalization". He oversees the Group's daily operations, advances major decisions on corporate strategy, personnel appointments, and investment integration, and comprehensively manages the Group's subsidiary member companies. He is building a professional management team to further enhance organizational efficiency, drive innovative business, link external cooperation, and advance the Group's global innovation process, committed to building an international innovative pharmaceutical company of China.
Mr. Eric Tse leads the company in unswervingly following the path of innovation and transformation, and building long-term core competitive advantages through comprehensive innovation. Sino Biopharm and its subsidiaries, such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., uphold the mission of "improving the quality of life and protecting the dignity of human life". Guided by societal clinical medication needs, they focus on the four major areas of oncology, hepatology, respiratory, and surgery/analgesic. They advance internal innovation and business development in parallel, cultivate a new innovation ecosystem, shape world-leading innovative R&D capabilities, enhance the Group's core competitiveness with new quality productive forces, and continuously achieve outstanding accomplishments and innovative breakthroughs.
Under the leadership of Eric Tse, the proportion of R&D investment in innovative drugs at Sino Biopharmaceutical Limited has increased to over 80% of total R&D spending. The company has proactively invested in multiple new targets, new platforms, and new technologies with blockbuster potential. In the next three years, more than 10 innovative drugs are expected to be launched to serve patients. Leveraging the strong platform of Sino Biopharm, its subsidiaries Chia Tai Tianqing and Beijing Tide Pharmaceutical have developed steadily. For many consecutive years, they have been selected for authoritative industry lists such as the Top 100 Pharmaceutical Companies in China and the Best Industrial Enterprises for Pharmaceutical R&D Pipelines in China. They have undertaken more than 80 national and provincial science and technology projects and have received honors such as the "China Patent Gold Award" and the "National Science and Technology Progress Award".
While dedicated to corporate management, Mr. Eric Tse is passionate about and actively involved in youth work in Hong Kong and the Guangdong-Hong-Kong-Macao Greater Bay Area. He frequently speaks out in the Hong Kong media on important topics such as Hong Kong's integration into the national development strategy, the steady and long-term implementation of "One Country, Two Systems", and promoting Hong Kong's transition "from governance to prosperity", contributing to the long-term prosperity, stability, and continued brilliance of Hong Kong.
-
Invest in Shanghai, Create the Future Together! Mr. Eric Tse Attends 2026 Shanghai Global Investment Promotion Conference, Deepening Coordinated Development of Sino Biopharmaceutical Limited in Shanghai and Jiangsu 2026.03
On March 14, the 2026 Shanghai Global Investment Promotion Conference opened with a main promotion event at the Shanghai East International Business Cooperation Zone.View > -
Davos Media Focus | Eric Tse: Integrating Global Innovation Resources to Accelerate the Move Towards a World-Class Pharmaceutical Company 2026.01
During the World Economic Forum Annual Meeting 2026 (the "Winter Davos Forum"), Sino Biopharm's (1177.HK) active M&A transactions and globalized innovation strategy attracted attention from numerous media outlets at home and abroad.View > -
Eric Tse Attended Winter Davos Forum and Called for Mutual Trust and Recognition to Break Bottlenecks in Biopharmaceutical Globalization 2026.01
View > -
"2025 Science and Technology + New Quality Productive Forces Summit" Held in Hong Kong, Attended by Ms. Cheng Cheung Ling and Mr. Eric Tse Who Delivered Speeches 2025.12
On December 16, the "2025 Science and Technology + New Quality Productive Forces Summit", organized by the Hong Kong China Friendship Association, was held in Hong Kong.View > -
Sino Biopharm Appears at International Biopharma Industry Week Shanghai 2025, Eric Tse: Deeply Rooting and Broadly Connecting by Leveraging Shanghai as a Global Hub 2025.10
From October 13 to 17, the International Biopharma Industry Week Shanghai 2025 was held in Shanghai, marking the fifth consecutive year that Shanghai has hosted this global platform.View > -
Sino Biopharm Donates HK$10 Million in Cash and Medicine for Emergency Relief of Tai Po Fire in Hong Kong 2025.11
On November 26, a sudden fire broke out at Wang Fuk Court in Tai Po District, New Territories, Hong Kong, drawing concern from across the nation.View > -
Ta Kung Pao | Net Profit Doubles with 27.2% Surge in Innovative Product Revenue - Sino Biopharm Announces 2025 Interim Results 2025.08
Driven by the dual forces of policy support and innovation, the domestic pharmaceutical industry is accelerating its recovery. On August 18, Hong Kong-listed leading pharmaceutical company Sino Biopharm (01177.HK) announced its 2025 semi-annual results. In the first half of the year, the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively, marking three consecutive reporting periods of stable double-digit growth.View > -
Sino Biopharm 2024 Full-Year Results Announcement: Double-Digit Growth in Both Revenue and Net Profit, Innovative Product Revenue Exceeds 12 Billion, a New High 2025.03
On March 20, Sino Biopharm (HK.01177) released its 2024 annual results report, delivering an impressive "double-digit growth" across two key metrics: full-year revenue for 2024 reached RMB 28.87 billion, a year-on-year increase of 10.2%, hitting a record high; adjusted net profit attributable to owners of the parent company reached RMB 3.46 billion, a year-on-year increase of 33.5%.View > -
From "Leading Innovation" to "Investing in Innovation", Sino Biopharm Leading (Shanghai) Private Investment Fund Unveiled and Established 2025.04
On April 22, the Sino Biopharm Leading (Shanghai) Private Investment Fund (hereinafter referred to as the "Sino Biopharm Leading Fund") was unveiled and established in the Pudong New Area. This is a major initiative by Sino Biopharm to invest in, empower, and cultivate innovation, following its commitment to comprehensive innovation and the achievement of leapfrog innovative development.View > -
Mr. Eric Tse Attends Summer Davos Forum and Advocates for AI-Driven Innovation to Fast-Track New Drug R&D 2025.06
On June 24, the 16th Annual Meeting of the New Champions 2025 of the World Economic Forum (also known as the Summer Davos Forum) opened in Tianjin.View >